SCHEMBL10046771

SCHEMBL10046771

C=C(C)NCCCCOc1c(CC)cc(C(C)(C)C)cc1Cc1cc(C(C)(C)C)cc(C)c1OCCCCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR2 O95136 4/20 0.38
▸ S1PR1 P21453 4/20 0.38
▸ S1PR3 Q99500 4/20 0.38
▸ LPAR2 Q9HBW0 4/20 0.38
▸ NR5A2 O00482 1/20 0.34
▸ NR5A1 Q13285 1/20 0.34
▸ THRA P10827 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ CNR1 P21554 2/20 0.33
▸ CNR2 P34972 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ RXRA P19793 2/20 0.32
▸ PPARG P37231 1/20 0.32
▸ MTNR1A P48039 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046769 0.92 TLR4 (0.33) S1PR2S1PR1S1PR3LPAR2NR5A2
SCHEMBL13992486 0.79 TLR4 (0.33) S1PR2S1PR1S1PR3LPAR2SMN1; SMN2
SCHEMBL14213237 0.79 TLR4 (0.33) S1PR2S1PR1S1PR3LPAR2SMN1; SMN2
SCHEMBL13992491 0.77 TLR4 (0.34) SMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL13992488 0.76 CYP1A2 (0.34) NR5A2NR5A1SMN1; SMN2KDM4EGAA
SCHEMBL10046764 0.76 CYP1A2 (0.34) NR5A2NR5A1SMN1; SMN2KDM4EGAA
SCHEMBL15479693 0.74 BCHE (0.43) ALDH1A1KMT2AGAA
SCHEMBL14213236 0.73 TSHR (0.38) NR5A2NR5A1ALDH1A1MAPTKDM4E
SCHEMBL18539819 0.73 — —
SCHEMBL13992485 0.71 HTR1D (0.41) THRATHRBMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207228-B2 Calixarene-based peptide conformation mimetics, methods of use, and methods of making REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2012-06-26 — — US disclosed
US-20080300164-A1 Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2008-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300164-A1 Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making CLSPN, BID, CALU S1PR2 4043/4885S1PR1 3503/4885S1PR3 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback